NANOBIOTIX SA

Nanobiotix SA is a clinical-stage biotechnology company whose core product, NBTXR3, is a hafnium oxide nanoparticle designed to be activated by radiotherapy. The development, testing, and regulatory approval pathway for this and other therapeutic candidates inherently involves animal experimentation. Preclinical studies to evaluate the safety, biodistribution, and efficacy of such novel medical treatments are standard industry practice and are required by global health authorities like the FDA and EMA before human trials can commence.

The available evidence does not specify the scale, nature, or alternatives considered in Nanobiotix's animal testing protocols. The company's SEC filings reference the "exploitation" of NBTXR3, which includes the full spectrum of development activities. Without further public disclosure regarding its use of animal models, the company's operations fall under the broad commercial exploitation of animals for product development and commercialization.